Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group
about
sameAs
Treatment of Acute Myeloid Leukemia in Adolescent and Young Adult PatientsHow I treat pediatric acute myeloid leukemiaChildhood acute myeloid leukaemiaCurrent Management of Childhood Acute Myeloid Leukemia.NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.Reduced-toxicity myeloablative conditioning consisting of 8-Gy total body irradiation, cyclophosphamide and fludarabine for pediatric hematological malignancies.High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia.Survival of Mexican children with acute myeloid leukaemia who received early intensification chemotherapy and an autologous transplantThe role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study.Lessons from the past: opportunities to improve childhood cancer survivor care through outcomes investigations of historical therapeutic approaches for pediatric hematological malignancies.Lessons learned from the investigational device exemption review of Children's Oncology Group trial AAML1031Development of treatment and clinical results in childhood acute myeloid leukemia in Poland.Outcome of transplantation for acute myelogenous leukemia in children with Down syndrome.Allogeneic hematopoietic cell transplantation in first remission abrogates poor outcomes associated with high-risk pediatric acute myeloid leukemia.Comparable survival for pediatric acute myeloid leukemia with poor-risk cytogenetics following chemotherapy, matched related donor, or unrelated donor transplantation.Pediatric acute myeloid leukemia.Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia.A critical review of which children with acute myeloid leukaemia need stem cell procedures.New approaches for the immunotherapy of acute myeloid leukemia.An overview of the potential strategies for NK cell-based immunotherapy for acute myeloid leukemia.Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents.Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis.Cell therapies for hematological malignancies: don't forget non-gene-modified t cells!Intravital longitudinal wide-area imaging of dynamic bone marrow engraftment and multilineage differentiation through nuclear-cytoplasmic labeling.Hematopoietic stem cell transplantation in pediatric patients with acute myeloid leukemia without favorable cytogenetics.Minimal residual disease of leukemia and the quality of cryopreserved human ovarian tissue in vitro.Increased p53 protein expression as a potential predictor of early relapse after hematopoietic stem cell transplantation in children with acute myelogenous leukemia.Similar outcomes of allogeneic hematopoietic cell transplantation from unrelated donor and umbilical cord blood vs. sibling donor for pediatric acute myeloid leukemia: Multicenter experience in China.Outcome of children with high-risk acute myeloid leukemia given autologous or allogeneic hematopoietic cell transplantation in the aieop AML-2002/01 study.
P2860
Q26799609-79EA6E75-9094-4496-B997-298B5D1B58A9Q26992280-F9931100-0DC6-4051-ADF7-EC6C5D19EE42Q27005960-CBF83C54-8122-4721-964B-1929B6906F92Q30244036-435108C1-7D72-4B73-AD89-E7388AFBDB3AQ33710760-35E1F497-FBAB-45C1-A2DB-2441BD6CA653Q33754603-6188B6AA-9A74-4C62-8DAA-FF39536B926EQ34460533-69BF4278-C06B-49BE-AA44-F27B1E0BD174Q35112199-6CB67FDE-BC89-4146-972F-D46E065D3050Q35189037-2EAEB9AC-1671-46FE-B322-E2328D82BD3BQ35643005-89C70603-5142-4C23-8415-138345C7E4D3Q35667279-CB5D60FC-B4F9-4196-A76B-E1E5330EE9F3Q35848149-9AAC2530-0975-4669-AD87-B612B9CEAFBDQ36736376-1DEF8111-71EC-4EEB-9489-4A48B349F396Q37000896-E4B30EBD-C3FF-4AE5-B47B-67DFE3E06689Q37017217-324A0DAF-438C-4B86-A037-688E0C01EF41Q37575215-29135A8A-AEDA-4CB9-9E55-48FB2C7DF728Q37988570-BCFBE9E2-1D27-4E69-8C07-BA3D4C2C21ADQ38196743-D2CBD224-3CAE-4705-99E1-31B151C98D01Q38205864-7342B76D-A3FD-4426-8A64-5BD5861693E0Q38482206-8517C581-867E-4B93-AE7E-9575AF06CA92Q38930242-5B3A0E0B-8E2E-4583-BAFE-AB28A4C05C82Q41643112-FB380BC2-096D-44ED-8D9A-7C2A0F26DC11Q45874732-3F91B39B-1818-474D-9189-1C349080A7D5Q47289766-E105541B-E434-4882-A162-6501A493538AQ47383761-8EBF0C3B-3701-4B9A-8B20-BF07360C5233Q48314617-7D7B000C-18E5-4F07-932C-278D55059472Q50959012-54DF4F35-1EB4-428A-BE07-5C48B43A5CEDQ52912438-E91FF8F4-4B43-4286-9563-CDBF492F8D2FQ53533468-08F19E4E-E21F-4F95-BFDE-8B402BF2EF7DQ54310310-DBBE20B1-CB9A-4607-8CCD-066650F9FC76
P2860
Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group
description
2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2008
@ast
scientific article (publication date: 10 December 2008)
@en
vedecký článok (publikovaný 2008/12/10)
@sk
vědecký článek publikovaný v roce 2008
@cs
wetenschappelijk artikel (gepubliceerd op 2008/12/10)
@nl
wissenschaftlicher Artikel
@de
наукова стаття, опублікована в грудні 2008
@uk
مقالة علمية (نشرت في 10-12-2008)
@ar
name
Impact of disease risk on effi ...... the Children's Oncology Group
@ast
Impact of disease risk on effi ...... the Children's Oncology Group
@en
Impact of disease risk on effi ...... the Children's Oncology Group
@nl
type
label
Impact of disease risk on effi ...... the Children's Oncology Group
@ast
Impact of disease risk on effi ...... the Children's Oncology Group
@en
Impact of disease risk on effi ...... the Children's Oncology Group
@nl
prefLabel
Impact of disease risk on effi ...... the Children's Oncology Group
@ast
Impact of disease risk on effi ...... the Children's Oncology Group
@en
Impact of disease risk on effi ...... the Children's Oncology Group
@nl
P2093
P2860
P356
P1476
Impact of disease risk on effi ...... the Children's Oncology Group
@en
P2093
Beverly J Lange
David Becton
Franklin O Smith
Gary H Lyman
John T Horan
Robert B Gerbing
Todd A Alonzo
William G Woods
Yaddanapudi Ravindranath
P2860
P304
P356
10.1200/JCO.2007.13.5244
P407
P577
2008-12-10T00:00:00Z